← Back to Screener
Merck & Co., Inc. (MRK)
Price$120.79
Value ScoreC
Growth ScoreC
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)7.30%
Price vs S&P 500 (4W)8.46%
VGM Score57.18
Market Capitalization$298.33B
P/E Ratio (Annual)16.34x
Indicated Dividend Yield (Annual)2.83%
All Metrics
P/CF (Annual)18.11x
Book Value / Share (Quarterly)$18.58
P/TBV (Annual)10.08x
Indicated Dividend (Annual)$3.40
Revenue Growth (3Y)3.12%
Cash Flow / Share (Quarterly)$5.72
Payout Ratio (TTM)44.79%
Price vs S&P 500 (YTD)6.60%
Gross Margin (TTM)78.07%
Net Profit Margin (TTM)13.59%
EPS (TTM)$3.55
10-Day Avg Trading Volume11.56M
EPS Excl Extra (TTM)$3.55
Revenue Growth (5Y)9.38%
EPS (Annual)$7.28
Dividend / Share (Annual)$3.27
ROI (Annual)17.91%
Gross Margin (Annual)77.08%
Net Profit Margin (5Y Avg)21.33%
Cash / Share (Quarterly)$2.31
P/E Basic Excl Extra (TTM)33.39x
Revenue Growth QoQ (YoY)4.87%
EPS Growth (5Y)21.23%
P/E Normalized (Annual)16.34x
ROA (Last FY)13.34%
Revenue Growth TTM (YoY)2.89%
EBITD / Share (TTM)$6.05
ROE (5Y Avg)27.67%
Operating Margin (TTM)18.18%
Cash Flow / Share (Annual)$4.99
P/B Ratio6.50x
P/B Ratio (Quarterly)6.48x
Net Income / Employee (Annual)$243,400
EV / Revenue (TTM)5.20x
Net Interest Coverage (TTM)22.74x
ROA (TTM)6.97%
EPS Growth QoQ (YoY)-19.34%
EV / EBITDA (TTM)22.69x
EPS Incl Extra (Annual)$7.28
Current Ratio (Annual)1.54x
Quick Ratio (Quarterly)1.06x
3-Month Avg Trading Volume10.64M
52-Week Price Return55.62%
EV / Free Cash Flow (Annual)27.68x
P/E Incl Extra (TTM)33.39x
Revenue / Employee (TTM)$876,900
Tangible BV / Share (Quarterly)$8.15
P/S Ratio (Annual)4.59x
Asset Turnover (Annual)0.47x
52-Week High$125.14
Operating Margin (5Y Avg)24.53%
EPS Excl Extra (Annual)$7.28
CapEx CAGR (5Y)-1.47%
Tangible BV CAGR (5Y)19.33%
26-Week Price Return15.22%
Quick Ratio (Annual)1.30x
13-Week Price Return4.07%
Total Debt / Equity (Annual)0.94x
Current Ratio (Quarterly)1.30x
Enterprise Value$342.12B
Revenue / Share Growth (5Y)9.68%
Asset Turnover (TTM)0.51x
Book Value / Share Growth (5Y)16.27%
Revenue / Employee (Annual)$866,800
Inventory Turnover (Annual)2.33x
Pretax Margin (Annual)32.41%
Cash / Share (Annual)$5.89
3-Month Return Std Dev27.43%
Gross Margin (5Y Avg)74.30%
Net Income / Employee (TTM)$119,100
EBITDA CAGR (5Y)29.58%
ROE (Last FY)34.70%
Net Interest Coverage (Annual)5.24x
EPS Basic Excl Extra (Annual)$7.28
P/FCF (TTM)21.14x
Receivables Turnover (TTM)5.72x
EV / Free Cash Flow (TTM)24.24x
Total Debt / Equity (Quarterly)1.07x
EPS Incl Extra (TTM)$3.55
Receivables Turnover (Annual)5.90x
ROI (TTM)9.54%
Dividend Growth Rate (5Y)5.92%
P/S Ratio (TTM)4.54x
Pretax Margin (5Y Avg)24.57%
Revenue / Share (Annual)$25.93
Tangible BV / Share (Annual)$10.48
Forward P/E17.07x
Free OCF CAGR (5Y)16.24%
Price vs S&P 500 (52W)31.25%
P/E Ratio (TTM)33.39x
EPS Growth TTM (YoY)-48.26%
Year-to-Date Return14.75%
5-Day Price Return4.88%
EPS Normalized (Annual)$7.28
ROA (5Y Avg)10.79%
Net Profit Margin (Annual)28.08%
Month-to-Date Return1.74%
Cash Flow / Share (TTM)$3.33
EBITD / Share (Annual)$9.68
EPS Growth (3Y)8.43%
Operating Margin (Annual)32.64%
LT Debt / Equity (Annual)0.89x
P/CF (TTM)16.68x
ROI (5Y Avg)15.23%
P/E Excl Extra (TTM)33.39x
LT Debt / Equity (Quarterly)1.02x
EPS Basic Excl Extra (TTM)$3.55
P/TBV (Quarterly)14.76x
Payout Ratio (Annual)44.79%
P/B Ratio (Annual)4.97x
Dividend / Share (TTM)$3.30
Inventory Turnover (TTM)2.28x
Pretax Margin (TTM)17.68%
Book Value / Share (Annual)$21.26
Price vs S&P 500 (13W)-4.19%
Net Margin Growth (5Y)10.53%
Dividend Yield (TTM)2.76%
Beta0.22x
P/FCF (Annual)24.14x
Revenue / Share (TTM)$26.61
ROE (TTM)17.93%
52-Week Low$76.66
vGradeC
gGradeC
mGradeB
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-1.28est. -1.52
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
3.85
3.89
3.91
3.94
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
MRKMerck & Co., Inc. | C | C | B | $120.79 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | B | $34.19 |
About
Merck is a diversified pharmaceutical company with a leading immuno-oncology franchise anchored by Keytruda, a substantial vaccine business including Gardasil, and cardiometabolic disease treatments. The company also operates animal health segments globally, with 47% of revenue derived from US human pharmaceuticals and vaccines.